Cargando…
SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
BACKGROUND: There is a lack of data on SARS-CoV-2 vaccination safety in children and young people (CYP) with rheumatic and musculoskeletal diseases (RMDs). Current vaccination guidance is based on data from adults with RMDs or CYP without RMDs. OBJECTIVES: To describe the safety of SARS-COV-2 vaccin...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344592/ https://www.ncbi.nlm.nih.gov/pubmed/35908834 http://dx.doi.org/10.1136/rmdopen-2022-002322 |
_version_ | 1784761254692257792 |
---|---|
author | Lawson-Tovey, Saskia Machado, Pedro M Strangfeld, Anja Mateus, Elsa Gossec, Laure Carmona, Loreto Raffeiner, Bernd Bulina, Inita Clemente, Daniel Zepa, Julija Rodrigues, Ana M. Mariette, Xavier Hyrich, Kimme L |
author_facet | Lawson-Tovey, Saskia Machado, Pedro M Strangfeld, Anja Mateus, Elsa Gossec, Laure Carmona, Loreto Raffeiner, Bernd Bulina, Inita Clemente, Daniel Zepa, Julija Rodrigues, Ana M. Mariette, Xavier Hyrich, Kimme L |
author_sort | Lawson-Tovey, Saskia |
collection | PubMed |
description | BACKGROUND: There is a lack of data on SARS-CoV-2 vaccination safety in children and young people (CYP) with rheumatic and musculoskeletal diseases (RMDs). Current vaccination guidance is based on data from adults with RMDs or CYP without RMDs. OBJECTIVES: To describe the safety of SARS-COV-2 vaccination in adolescents with inflammatory RMDs and adults with juvenile idiopathic arthritis (JIA). METHODS: We described patient characteristics, flares and adverse events (AEs) in adolescent cases under 18 with inflammatory RMDs and adult cases aged 18 or above with JIA submitted to the European Alliance of Associations for Rheumatology COVAX registry. RESULTS: A total of 110 cases were reported to the registry. Thirty-six adolescent cases were reported from four countries, most with JIA (42%). Over half (56%) reported early reactogenic-like AEs. One mild polyarthralgia flare and one serious AE of special interest (malaise) were reported. No CYP reported SARS-CoV-2 infection postvaccination. Seventy-four adult JIA cases were reported from 11 countries. Almost two-thirds (62%) reported early reactogenic-like AEs and two flares were reported (mild polyarthralgia and moderate uveitis). No serious AEs of special interest were reported among adults with JIA. Three female patients aged 20–30 years were diagnosed with SARS-CoV-2 postvaccination; all fully recovered. CONCLUSIONS: This is an important contribution to research on SARS-CoV-2 vaccine safety in adolescents with RMDs and adults with JIA. It is important to note the low frequency of disease flares, serious AEs and SARS-CoV-2 reinfection seen in both populations, although the dataset is limited by its size. |
format | Online Article Text |
id | pubmed-9344592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-93445922022-08-02 SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry Lawson-Tovey, Saskia Machado, Pedro M Strangfeld, Anja Mateus, Elsa Gossec, Laure Carmona, Loreto Raffeiner, Bernd Bulina, Inita Clemente, Daniel Zepa, Julija Rodrigues, Ana M. Mariette, Xavier Hyrich, Kimme L RMD Open Infections BACKGROUND: There is a lack of data on SARS-CoV-2 vaccination safety in children and young people (CYP) with rheumatic and musculoskeletal diseases (RMDs). Current vaccination guidance is based on data from adults with RMDs or CYP without RMDs. OBJECTIVES: To describe the safety of SARS-COV-2 vaccination in adolescents with inflammatory RMDs and adults with juvenile idiopathic arthritis (JIA). METHODS: We described patient characteristics, flares and adverse events (AEs) in adolescent cases under 18 with inflammatory RMDs and adult cases aged 18 or above with JIA submitted to the European Alliance of Associations for Rheumatology COVAX registry. RESULTS: A total of 110 cases were reported to the registry. Thirty-six adolescent cases were reported from four countries, most with JIA (42%). Over half (56%) reported early reactogenic-like AEs. One mild polyarthralgia flare and one serious AE of special interest (malaise) were reported. No CYP reported SARS-CoV-2 infection postvaccination. Seventy-four adult JIA cases were reported from 11 countries. Almost two-thirds (62%) reported early reactogenic-like AEs and two flares were reported (mild polyarthralgia and moderate uveitis). No serious AEs of special interest were reported among adults with JIA. Three female patients aged 20–30 years were diagnosed with SARS-CoV-2 postvaccination; all fully recovered. CONCLUSIONS: This is an important contribution to research on SARS-CoV-2 vaccine safety in adolescents with RMDs and adults with JIA. It is important to note the low frequency of disease flares, serious AEs and SARS-CoV-2 reinfection seen in both populations, although the dataset is limited by its size. BMJ Publishing Group 2022-07-29 /pmc/articles/PMC9344592/ /pubmed/35908834 http://dx.doi.org/10.1136/rmdopen-2022-002322 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Infections Lawson-Tovey, Saskia Machado, Pedro M Strangfeld, Anja Mateus, Elsa Gossec, Laure Carmona, Loreto Raffeiner, Bernd Bulina, Inita Clemente, Daniel Zepa, Julija Rodrigues, Ana M. Mariette, Xavier Hyrich, Kimme L SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry |
title | SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry |
title_full | SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry |
title_fullStr | SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry |
title_full_unstemmed | SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry |
title_short | SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry |
title_sort | sars-cov-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the eular covax physician-reported registry |
topic | Infections |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344592/ https://www.ncbi.nlm.nih.gov/pubmed/35908834 http://dx.doi.org/10.1136/rmdopen-2022-002322 |
work_keys_str_mv | AT lawsontoveysaskia sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT machadopedrom sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT strangfeldanja sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT mateuselsa sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT gosseclaure sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT carmonaloreto sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT raffeinerbernd sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT bulinainita sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT clementedaniel sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT zepajulija sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT rodriguesanam sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT mariettexavier sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT hyrichkimmel sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry AT sarscov2vaccinesafetyinadolescentswithinflammatoryrheumaticandmusculoskeletaldiseasesandadultswithjuvenileidiopathicarthritisdatafromtheeularcovaxphysicianreportedregistry |